2025-09-30 Investor Notice of the 28th Annual General Meeting of Shareholders 2025-09-25 Investor Consolidated Financial Results for the Year Ended July 31, 2025 (Based on Japanese GAAP) 2025-09-24 Research and Development “ALAgene® technology”-Derived Antibody Therapeutic Candidate Achieves Phase I Clinical Milestone ～Driving Future Growth through Strategic License Agreement～ 2025-09-19 Investor Notice Regarding the Board of Directors’ Opinion on a Shareholder Proposal 2025-09-19 Investor Notice Regarding Partial Amendments to the Articles of Incorporation 2025-09-11 Investor [Summary] Consolidated Financial Results for the Fiscal Year Ended July 31, 2025 (Under Japanese GAAP) 2025-09-08 Investor Notice Regarding Revision of Full-Year Financial Results Forecast for the Fiscal Year Ended July 2025 2025-09-08 Investor Notice Regarding Special Loss (non-consolidated) due to Impairment of Investment in a Subsidiary 2025-09-04 Investor Notice Regarding Execution of Loan Agreement with Financial Covenants 2025-08-19 Investor Notice Regarding Construction of a New Plant by Our Consolidated Subsidiary and Execution of a Loan Agreement with Financial Covenants More